Treatment of adult t cell leukemia/lymphoma (atll) using mir-155 inhibitors

Abstract

The present disclosure provides methods for treating Adult T-cell Leukemia/Lymphoma (ATLL) in a subject by administering to the subject an oligonucleotide inhibitor of miR-155. In some embodiments, the subject may have received one or more therapies for treating ATLL prior to receiving the oligonucleotide inhibitor of miR-155. Administration of an oligonucleotide inhibitor of miR-155 according to the methods of the present disclosure can decrease the tumor cell count or can maintain the tumor cell count at or below the tumor cell count at the beginning of administration of the oligonucleotide inhibitor of miR-155. Accordingly, the methods provided in this disclosure can be used as maintenance therapies for treating ATLL subjects.

Dependencies are inferred from the claim text.